Gain Therapeutics (GANX)
(Delayed Data from NSDQ)
$1.58 USD
-0.12 (-7.06%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.60 +0.02 (1.27%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GANX 1.58 -0.12(-7.06%)
Will GANX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GANX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GANX
All You Need to Know About Gain Therapeutics (GANX) Rating Upgrade to Strong Buy
Best Momentum Stocks to Buy for January 9th
GANX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for GANX
GANX Fell Below 50 Day Moving Average on September 19
GANX Crossed Above 50 Day Moving Average on September 19
GANX forms Directional Movement Crossover Bearish on September 17
Gain Therapeutics (GANX) Extends Phase 1b Study for Parkinson's Treatment
Gain Therapeutics begins GT-02287 Phase 1b extension study in Parkinson’s